Announcements Trials
Browse Landscape

Phase

Phase 1 15Phase 2 3Phase 1/2 3Phase 3 1

Status

Withdrawn 3Completed 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Ovarian Neoplasms 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × navitoclax × Clear all
NCT02591095 2019-03-19

MONAVI-1

Centre Francois Baclesse

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms

NCT01087151 2016-11-02

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Genentech, Inc.

Phase 2 Completed
118 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01557777 2014-07-04

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

AbbVie

Phase 2 Completed
17 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡